168 related articles for article (PubMed ID: 19654286)
1. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance.
Nomura M; Ishii H; Kawakami A; Yoshida M
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1030-8. PubMed ID: 19654286
[TBL] [Abstract][Full Text] [Related]
2. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
3. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
[TBL] [Abstract][Full Text] [Related]
4. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed MH; Byrne CD
Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
[TBL] [Abstract][Full Text] [Related]
6. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yasuda O; Ogawa H; Kim-Mitsuyama S
J Pharmacol Exp Ther; 2010 Oct; 335(1):70-5. PubMed ID: 20651026
[TBL] [Abstract][Full Text] [Related]
7. Niemann-Pick C1-like 1 overexpression facilitates ezetimibe-sensitive cholesterol and beta-sitosterol uptake in CaCo-2 cells.
Yamanashi Y; Takada T; Suzuki H
J Pharmacol Exp Ther; 2007 Feb; 320(2):559-64. PubMed ID: 17135346
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Niemann-Pick C1-like 1.
Pramfalk C; Jiang ZY; Parini P
Curr Opin Lipidol; 2011 Jun; 22(3):225-30. PubMed ID: 21494140
[TBL] [Abstract][Full Text] [Related]
9. In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs.
Hawes BE; O'neill KA; Yao X; Crona JH; Davis HR; Graziano MP; Altmann SW
Mol Pharmacol; 2007 Jan; 71(1):19-29. PubMed ID: 17005902
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
11. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
12. Niemann-pick C1-like 1 mediates alpha-tocopherol transport.
Narushima K; Takada T; Yamanashi Y; Suzuki H
Mol Pharmacol; 2008 Jul; 74(1):42-9. PubMed ID: 18403720
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver.
Tang W; Jia L; Ma Y; Xie P; Haywood J; Dawson PA; Li J; Yu L
Biochim Biophys Acta; 2011 Sep; 1811(9):549-55. PubMed ID: 21683156
[TBL] [Abstract][Full Text] [Related]
14. Ezetimibe inhibits hepatic Niemann-Pick C1-Like 1 to facilitate macrophage reverse cholesterol transport in mice.
Xie P; Jia L; Ma Y; Ou J; Miao H; Wang N; Guo F; Yazdanyar A; Jiang XC; Yu L
Arterioscler Thromb Vasc Biol; 2013 May; 33(5):920-5. PubMed ID: 23471229
[TBL] [Abstract][Full Text] [Related]
15. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
Yoshida M
Curr Vasc Pharmacol; 2011 Jan; 9(1):121-3. PubMed ID: 21044016
[TBL] [Abstract][Full Text] [Related]
16. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1.
Ge L; Wang J; Qi W; Miao HH; Cao J; Qu YX; Li BL; Song BL
Cell Metab; 2008 Jun; 7(6):508-19. PubMed ID: 18522832
[TBL] [Abstract][Full Text] [Related]
17. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.
Jia L; Betters JL; Yu L
Annu Rev Physiol; 2011; 73():239-59. PubMed ID: 20809793
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress impairs HIF1α activation: a novel mechanism for increased vulnerability of steatotic hepatocytes to hypoxic stress.
Anavi S; Harmelin NB; Madar Z; Tirosh O
Free Radic Biol Med; 2012 May; 52(9):1531-42. PubMed ID: 22343340
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe.
Temel RE; Tang W; Ma Y; Rudel LL; Willingham MC; Ioannou YA; Davies JP; Nilsson LM; Yu L
J Clin Invest; 2007 Jul; 117(7):1968-78. PubMed ID: 17571164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
